Business Development Director Nordics

MAPI is structured into three divisions which comprise a number of separate legal entities:

Late Phase CRO

• Phase IV Clinical Trials
• Observation and Registry studies

Strategic Consulting

• Market Access
• Cost effectiveness evidence generation

Linguistic Validation

• Patient reported and clinical assessments for appropriate cross-cultural use and interpretation

A separate entity, the MAPI RESEARCH TRUST is a non-profit association concerned with the promotion of PRO evaluations and worldwide distribution of information concerning these measures.

The MAPI Group consists of a number of companies; all dedicated to providing unique solutions to aid and improve drug development to meet patient and market needs.

MAPI group anticipates change and develops services and solutions designed to respond to a full range of evaluation needs. Their experience comes from extensive partnerships with industry, health authorities, investigators and patients.

MAPI Group’s strength lies not only in its breadth of experience and expertise, but in the total dedication to research conducted by dynamic, specialised teams, backed up by powerful technical and logistics support.

REGISTRAT-MAPI

REGISTRAT-MAPI is the industry’s largest clinical research organisation dedicated solely to “real world” clinical research. Successfully drawing upon their strategic and operational expertise to design and conduct global late phase studies and to develop partnerships with biopharmaceutical and medical device company clients.

As the demand for Late Phase development grows significantly both in size and complexity, REGISTRAT-MAPI continues to lead the way through innovation in registries, safety studies and product utilisation studies.

With its head office in Lyon, France and further operations throughout Europe and United-States, REGISTRAT-MAPI specialise, among others, in:

• Pharmaco-epidemiological Studies
• Disease and Product Registries

Providing a complete Spectrum of Integrated Late Phase Services:

• Strategic Consulting Services
• Risk Evaluation and Medical Strategies
• Optimal Study Design
• Multidisciplinary Excellence in Patient Reported Outcomes
• Multi-country Regulatory Management & Ethical Submissions
• Accurate Implementation Process & Project Management
• In Fine PHARMA : network of 2000 pharmacists in France
• Remote and on-site monitoring
• Tailored integrated EDC & Call Centre solutions
• Data Management Services
• Late Phase oriented Statistical Methods
• Medical Writing, Publications
• Integrated Technologies

Evidence-based research is increasingly desired by pharmaceutical companies due to recent FDA and EMEA initiatives as well as changing requirements from health care payers (government and private insurers). The market for phase IV post-approval research is estimated at $12 billion and growing at 23% per year . REGISTRAT-MAPI is currently the market leader in France and a major player in Europe in Late Phase studies (Phase IV and Observational).

Given REGISTRAT-MAPI’s leading position in Europe, unique range of expertise and experience already gained through its numerous key clients, the Group is well positioned to win large scale international studies, negotiate preferred provider agreements and become a leading global player in the Late Phase segment.

It is widely recognised that the demand for CRO services will continue to grow over the coming years with some predicting that this will be as much as 20% per annum . The market for Phase IV post-approval research is estimated at $12bn and growing by 23% per year . REGISTRAT-MAPI is uniquely positioned to take advantage of this growth for several reasons:

• They are the industry’s largest clinical research organisation dedicated solely to “real world” clinical research and have the expertise and infrastructure required to perform large, multinational observational studies and registries.
• They have more than two hundred specialist employees in 7…